- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
CHPA study: OTC decongestant is effective
A new meta-analysis conducted by the Consumer Healthcare Products Association (CHPA) shows that phenylephrine, a popular decongestant in OTC cold and allergy remedies, is effective at relieving nasal congestion. The results confirm the assertion by the FDA on the efficacy of phenylephrine at a 10-mg dose. Commenting on the study, Linda Suydam, CHPA president, said, "Phenylephrine has been relieving people's congestion for decades, and this meta-analysis reaffirms that. The FDA has ruled that phenylephrine is safe and effective based on its own thorough review; we now add this critical meta-analysis to its files to further support that ruling." The meta-analysis refutes the contention that phenylephrine in its 10-mg dose does not provide effective nasal decongestion. Last July, a Florida pharmacist made that assertion in a letter to the editor of a medical journal. He since has called on the FDA to raise the standard dose to 25 mg and require further studies of the higher dose's safety and efficacy.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Antiseizure Medications Linked to Serious Potential Reaction, FDA Warns
November 30th 2023Levetiracetam and clobazam can cause Drug Reaction with Eosinophilia and Systemic Symptoms, which can start as a rash but progress quickly, potentially resulting in injury to internal organs, hospitalization, and death.
Examining Barriers to Care in Diabetic Retinopathy Screening
November 30th 2023Prior research has shown the association between various socioeconomic variables and lower adherence to diabetic retinopathy screening, but few have elaborated on the patient perspective to understand the reason behind this association.
